AI assistant
Sending…
Transcode Therapeutics, Inc. — Director's Dealing 2025
Dec 22, 2025
35264_dirs_2025-12-22_ba27a01a-ed47-445a-9fc8-5075685de553.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Transcode Therapeutics, Inc. (RNAZ)
CIK: 0001829635
Period of Report: 2025-12-19
Reporting Person: STOVER JACK E (Director)
More from Transcode Therapeutics, Inc.
Proxy Solicitation & Information Statement
2026
May 26
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 22
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 7
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Feb 23
Regulatory Filings
2026
Feb 5
Major Shareholding Notification
2026
Jan 7